German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it ...

BioNTech is buying fellow German mRNA vaccine developer CureVac in all-stock transaction that values the acquired biotech at ...

German pharmaceutical firm BioNTech, one of the first companies worldwide to develop an effective coronavirus vaccine, is looking to acquire its domestic rival CureVac, the firm said on Thursday.

Valued at $1.25 billion, the deal expands BioNTech’s cancer drug portfolio and heads off royalty costs it could have owed ...

Multiple new members have voiced anti-vaccine views that are not based in scientific evidence. Their actions could shape the ...

Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, the companies said Thursday, bringing together two ...

Novavax's COVID-19-influenza vaccines show strong immune response in older adults, paving the way for regulatory approval.

CureVac about a year ago opted to focus on oncology when it agreed to sell its remaining influenza and COVID-19 vaccine ...

BioNTech said Thursday it would buy CureVac, its onetime competitor in the Covid-19 vaccine race, for about $1.25 billion in ...

S hares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach after U.S.

CureVac (CVAC) stock jumps as BioNTech (BNTX) agrees to acquire in an all-stock deal worth $1.25B. Read more here.